Dicerna Pharmaceuticals (DRNA) PT Raised to $38 at Truist Securities, Following Acquisition
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
